Document is current
Any future updates will be listed below
-
Authors
Fazekas, Tamás
Széles, Ádám D.
Teutsch, Brigitta http://orcid.org/0000-0002-9530-7886
Csizmarik, Anita
Vékony, Bálint http://orcid.org/0000-0002-6814-7311
Váradi, Alex
Kói, Tamás
Lang, Zsolt
Ács, Nándor
Kopa, Zsolt
Hegyi, Péter
Hadaschik, Boris
Grünwald, Viktor http://orcid.org/0000-0003-2083-7687
Nyirády, Péter
Szarvas, Tibor http://orcid.org/0000-0002-6321-0799
- License Information
-
More Information
Article History
Received: 6 September 2022
Revised: 22 November 2022
Accepted: 29 November 2022
First Online: 12 December 2022
Competing interests
: BH has had advisory roles for ABX, AAA/Novartis, Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Janssen R&D, Lightpoint Medical, Inc., and Pfizer; has received research funding from Astellas, Bristol Myers Squibb, AAA/Novartis, German Research Foundation, Janssen R&D, and Pfizer; and has received compensation for travel from Astellas, AstraZeneca, Bayer and Janssen R&D.
: No ethical approval was required for this systematic review with meta-analysis, as all data were already published in peer-reviewed journals. No patients were involved in the design, conduct or interpretation of our study. The datasets used in this study can be found in the full-text paper included in the systematic review and meta-analysis.
